

1 Article

## 2 Evolution of human respiratory syncytial virus (RSV) 3 over multiple seasons in New South Wales, Australia

4

5 Francesca Di Giallonardo<sup>1,2</sup>, Jen Kok<sup>3</sup>, Marian Fernandez<sup>3</sup>, Ian Carter<sup>3</sup>, Jemma L. Geoghegan<sup>4</sup>,  
6 Dominic E. Dwyer<sup>3</sup>, Edward C. Holmes<sup>1</sup> and John-Sebastian Eden<sup>1,5\*</sup>

7

8 <sup>1</sup>Marie Bashir Institute for Infectious Diseases and Biosecurity, Charles Perkins Centre, School of  
9 Life and Environmental Sciences and Sydney Medical School, The University of Sydney, Sydney,  
10 NSW 2006, Australia. (E.C.H.) edward.holmes@sydney.edu.au

11 <sup>2</sup>The Kirby Institute, University of New South Wales, Randwick, NSW 2052, Australia. (F.D.G.)  
12 fdigiallonardo@kirby.unsw.edu.au

13 <sup>3</sup>Institute for Clinical Pathology and Medical Research, NSW Health Pathology, Westmead Hospital  
14 and University of Sydney, Sydney, NSW 2145, Australia. (J.K.) jen.kok@health.nsw.gov.au; (M.F.)  
15 marian.fernandez@health.nsw.gov.au; (I.C.) ian.carter@health.nsw.gov.au; (D.E.D)  
16 dominic.dwyer@sydney.edu.au

17 <sup>4</sup>Department of Biological Sciences, Macquarie University, Sydney, NSW 2109, Australia. (J.L.G.)  
18 jemma.geoghegan@mq.edu.au

19 <sup>5</sup>Centre for Virus Research, Westmead Institute for Medical Research, Westmead, NSW 2145,  
20 Australia. (J-S.E) js.eden@sydney.edu.au

21 \*Correspondence: js.eden@sydney.edu.au; Tel.: +61 2 8627 1817

22

23

24 **Abstract:** There is an ongoing global pandemic of human respiratory syncytial virus (RSV) infection  
25 that results in substantial annual morbidity and mortality. In Australia, RSV is the major cause of  
26 acute lower respiratory tract infections (ALRI). Nevertheless, little is known about the extent and  
27 origins of genetic diversity of RSV in Australia, nor the factors that shape this diversity. We conducted  
28 a genome-scale analysis of RSV infections in New South Wales (NSW). RSV genomes were  
29 successfully sequenced for 144 specimens collected between 2010-2016. Of these, 64 belonged to the  
30 RSVA and 80 to the RSVB subtype. Phylogenetic analysis revealed a wide diversity of RSV lineages  
31 within NSW and that both subtypes evolved rapidly in a strongly clock-like manner, with mean rates  
32 of approximately  $6.8 \times 10^{-4}$  nucleotide substitutions per site per year. There was only weak evidence  
33 for geographic clustering of sequences, indicative of fluid patterns of transmission within the infected  
34 population, and no evidence of any clustering by patient age such that viruses in the same lineages  
35 circulate through the entire host population. Importantly, we show that both subtypes circulated  
36 concurrently in NSW with multiple introductions into the Australian population in each year, and  
37 only limited evidence for multi-year persistence.

38 **Keywords:** respiratory syncytial virus; phylogenetics; evolution; multi-year persistence

39

40

## 41 1. Introduction

42 Respiratory syncytial virus (RSV) is a major cause of acute respiratory tract infections (ARTI) in  
43 humans [1]. The burden of RSV disease is greatest in specific vulnerable populations, including  
44 young children and the elderly, particularly those with pre-existing medical comorbidities or who  
45 are immunocompromised. Outbreaks in hospitals and closed environments such as aged care  
46 facilities have also been documented [2]. Importantly, the annual global hospitalization rate of RSV  
47 infection in young children is nearly 10% and is associated with approximately 59,600 deaths [3, 4].  
48 The health and economic burden of RSV in young children surpasses that of influenza virus with  
49 total annual direct healthcare costs estimated to be between \$24 – 50 million [5]. In Australia,  
50 Indigenous children living in remote communities also experience a high prevalence of RSV,  
51 particularly in comparison to non-Indigenous groups [6, 7]. Morbidity and mortality is also high in  
52 elderly adults, with approximately 14,000 deaths annually due to RSV in the USA (Centre for Disease  
53 Control, [8]).

54 While the factors that contribute to the prevalence of RSV are yet to be fully defined; Immunity,  
55 re-infection rates, and climate may play a role. For example, laboratory reports highlight the  
56 seasonality in temperate regions in Australia, with a peak in RSV activity typically occurring in the  
57 early winter (May/June) period and preceding the seasonal peak in influenza virus (New South Wales  
58 Health, Influenza Monthly Surveillance Reports). Climate and rainfall differences in the tropical  
59 north of Australia are also likely to be important drivers of RSV disease patterns, resulting in a  
60 seasonality distinct from that observed in temperate regions, with a correlation between peak RSV  
61 and peak rainfall levels around January [6].

62 RSV is a negative-sense single-stranded RNA virus (family *Pneumoviridae*) with a 15 kb genome  
63 that encodes 10 proteins [9]. Two distinct antigenic subgroups have been identified, subtypes A and  
64 B (RSVA and RSVB, respectively) that show clear phylogenetic divergence [10, 11]. The glycoprotein  
65 (G), responsible for attachment to the host cell, exhibits the greatest genetic diversity within and  
66 between subtypes [11]. This is thought to reflect strong immune pressure and the subsequent  
67 generation of escape variants, in a process analogous to antigenic drift in the hemagglutinin (HA)  
68 protein in influenza A virus [12, 13]. Hence, reinfection with RSV is commonplace [14, 15]. There are  
69 currently no effective vaccines against RSV, although a number of novel vaccines are entering clinical  
70 trials [16]. Similarly, there are novel antivirals targeting the viral polymerase and fusion protein that  
71 are in clinical trials [17].

72 Despite the clinical significance and the burden of RSV infection worldwide, we lack  
73 understanding of the patterns of virus emergence, evolution and spread. Phylogenetic studies of  
74 global RSV evolution are compromised due to the limited availability of gene sequence data and  
75 strongly asynchronous sampling in time and space. Most evolutionary analyses have focused on the  
76 G gene because of its high genetic diversity and utility as a phylogenetic marker. The G gene is also  
77 characterized by premature stop codons in the case of RSVB [18, 19], and duplications in the G gene  
78 are described in both subtypes [20, 21]. Less is known about the genome-scale evolution of RSV [21-  
79 25], although this is necessary for defining fine-scale phylodynamic and epidemiological processes  
80 that may assist in targeted interventions including vaccine design and implementation [20, 22, 26].

81 There have been several studies of RSV evolution in specific geographic regions, including South  
82 Africa [25], the Netherlands [23], Argentina [21], Italy [24], and Kenya [22]. These studies highlight  
83 the global distribution of predominant RSV variants during each season, alongside the establishment

84 and co-circulation of local endemic sub-lineages. There is, however, limited data exploring the genetic  
85 diversity of RSV in Australia. Similarly, the evolution and spread of RSV within specific communities,  
86 and hence how long individual lineages of RSV are able to persist in single populations, is not well  
87 understood. To address these issues, we provide the first large, genome-scale analysis of RSV in  
88 Australia, focusing on infections identified through a major clinical diagnostic laboratory that  
89 services a population over 1.57 million people. In particular, we sought to determine the extent and  
90 pattern of genetic diversity circulating within the culturally diverse region of western Sydney as well  
91 as the rural region of western New South Wales (NSW), how this relates to the global diversity of the  
92 virus, what epidemiological factors act to shape genetic diversity at the local level, and to what extent  
93 RSV transmission persists between seasonal outbreaks.

## 94 **2. Materials and Methods**

### 95 *2.1 Ethics*

96 This study was approved by local ethics and governance committees (LNR/17/WMEAD/128;  
97 SSA/17/WMEAD/129). Samples were de-identified with basic demographic information collected  
98 including age, sex and location (city, region, hospital).

### 100 *2.2. Sample collection*

101 This study utilized residual RSV-positive specimens collected for routine diagnostic testing at  
102 the Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, NSW,  
103 Australia between May 2010 and December 2016. Viral nucleic acid that was previously extracted  
104 (NucliSENS® easyMAG®, bioMérieux) during routine diagnostic testing was stored at -80°C prior  
105 to the commencement of this study.

106

### 107 *2.3. Whole genome sequencing*

108 We employed an overlapping RT-PCR strategy to amplify viral genomes (four ~4kb amplicons),  
109 targeting both RSVA and RSVB subtypes with previously published primers [27]. Briefly, viral RNA  
110 was first reverse transcribed using a pool of the four forward primers (RSVS1\_01F, RSVS2\_3905F,  
111 RSVS3\_7215F and RSVS4\_10959F) and SuperScript™ IV cDNA synthesis system (Invitrogen,  
112 ThermoFisher Scientific). The resultant cDNA was then split across four parallel PCR reactions to  
113 amplify the genome using Platinum SuperFi (Invitrogen). For successfully amplified samples, the  
114 four amplicons were pooled equally and then prepared as libraries using Nextera XT before MiSeq  
115 (Illumina) sequencing. Each sequencing run contained between 41 and 60 indexed samples, which  
116 generated at least 2000X per base coverage per genome. Raw sequence reads were quality trimmed  
117 with Trimmomatic [28], and then *de novo* assembled using Trinity [29] and SPAdes [30]. The trimmed  
118 reads were re-mapped to draft RSV genome contigs with BowTie2 [31]. The mapping alignment  
119 quality was checked manually particularly around known G gene duplications before extracting the  
120 final majority consensus genome sequence for each sample.

121

### 122 *2.4. Data Availability*

123 All sequence reads generated in this project are available on NCBI GenBank (Submission ID  
124 2142716). Accession numbers will be available and listed in supplementary table 1.

125

126 *2.5. Phylogenetic analysis*

127 To place our sample set into a global context, complete and near complete genome sequences of  
128 RSVA and RSVB were obtained from GenBank. Sequences with no geographic association or  
129 sampling date were excluded. RSVA and RSVB sequences were aligned separately using the  
130 multiple-sequence alignment tool, MAFFT, using the L-INS-I algorithm followed by a visual  
131 inspection [32]. Sequences resulting from passaging experiments, or potential recombinants  
132 identified using RDP4 [33] were removed from the alignment. After this data pruning, the final data  
133 set consisted of 849 RSVA of 15,062 nt length and 500 RSVB genome sequences of 15,033 nt length  
134 (Table S1). Intergenic regions were removed for phylogenetic tree estimates as they contained single  
135 nucleotide insertions and deletions.

136 Maximum likelihood (ML) trees were estimated in RAxML [34, 35] employing a GTR gamma  
137 ( $\Gamma$ ) nucleotide substitution model and 1,000 bootstrap replications. To determine the extent of  
138 temporal structure in a data a root-to-tip regression of genetic distance against year of sampling was  
139 performed using TempEst v.1.5 utilizing the separate ML trees for RSVA and RSVB [36]. As both  
140 RSVA and RSVB exhibited strong temporal structure (i.e. clock-like evolution; see Results), we  
141 estimated their evolutionary rates more accurately using the Bayesian Markov chain Monte Carlo  
142 (MCMC) method implemented in BEAST v1.8.2 [37], using a HKY + gamma ( $\Gamma$ ) substitution model.  
143 A strict clock was used for the evolutionary rates estimates and a constant population size was  
144 implemented as a tree prior (although no significant differences in evolutionary rate were observed  
145 when we compared rate estimates from the uncorrelated log-normal relaxed clock to those from the  
146 strict clock). All analyses were run for at least 100 million steps and sampling every 10,000 steps to  
147 ensure convergence of all parameters. The first 10% of the posterior was removed as burn-in. Mean  
148 rates and 95% highest posterior density (HPD) were compared and values with HDP non-  
149 overlapping with mean rate values are significantly different. However, because we were unable to  
150 achieve consistent statistical convergence for the global data set, evolutionary rates were instead  
151 estimated by implementing a least-square dating algorithm (LSD) which is suitable for large data sets  
152 [38, 39]. To obtain significance, 1,000 parametric bootstraps were conducted on the branch lengths.  
153

154 *2.6. Phylogenetic analysis of clustering patterns*


155 We used a phylogenetic approach to determine whether there is more clustering by geography  
156 and age within the NSW RSV data set than might be expected from chance alone. Specifically,  
157 Bayesian posterior trees were used for evaluating geographic and age structure in the RSVA and  
158 RSVB trees using the Bayesian Tip-association Significance (BaTS) program, which compares  
159 parsimony score (PS), association index (AI), and maximum clade size (MC) statistics [40]. Estimates  
160 were repeated 1,000 times to infer significance. The traits investigated were age, the hospital facility  
161 where patients first presented, and state electorate. Because of large sampling biases in the data, with  
162 few sequences obtained from most years (Fig. 1A), this analysis was only performed on the samples  
163 from 2016 as it was by far the most densely sampled year (RSVA = 36 sequences, RSVB = 57).

164 **3. Results & Discussion**165 *3.1. Demographic characteristics of RSV in NSW*

166 We attempted whole genome sequencing on 241 archived RSV-positive viral nucleic acid  
167 extracts held and tested by ICPMR. Virus genomes were successfully sequenced for 144 specimens,

168 of which 64 belonged to RSVA and 80 to RSVB. The number of samples was skewed with the majority  
 169 collected in 2016, comprising 36 RSVA and 57 RSVB sequences, respectively (Figure 1A). Despite this  
 170 limited sampling, it is evident that RSVA and RSVB co-circulated in every season, which is consistent  
 171 with other molecular epidemiological studies [41-44]. A distinct seasonality was apparent with peaks  
 172 typically occurring in the early winter period (May to July) (Figure 1A). This pattern is consistent  
 173 with aggregated data from state-wide testing across NSW for RSV, influenza, and other respiratory  
 174 viruses (Figure 1B) [45]. For RSVA, 54.7% of the samples were derived from female patients, while  
 175 43.8% RSVB samples were from female patients (Table 1). Forty-five per cent of RSVA sequences  
 176 were obtained from patients under the age of two, and 27% from patients greater than 65 years of  
 177 age. These numbers were slightly lower for RSVB, with 43% being infants and only 20% older  
 178 patients. While all testing and sequencing was performed at Westmead Hospital, the cases were not  
 179 limited to the locations surrounding the hospital, but also included samples from western and north-  
 180 western rural NSW and hence some distance from metropolitan Sydney (Figure 2); as a consequence,  
 181 the samples collected here will be referred to as from NSW. The electorates with the most sequences  
 182 sampled were Orange ( $n = 10$ ) and Mount Druitt ( $n = 11$ ). Despite the wide geographic range of  
 183 sampling, coverage was low, hence, sequences were sampled only from a small number of  
 184 geographic locations.


185



186

187 **Figure 1. Incidence of RSV in New South Wales.** (A) Number of RSV genome sequences per four-  
 188 week period: RSVA = blue, RSVB = red. (B) Number of positive samples per 1,000 specimens reported

189 across NSW per four-week period: RSV = orange, Influenza = green, Other, including parainfluenza  
 190 virus, adenovirus, and human metapneumovirus, = grey.  
 191




192  
 193 **Figure 2. Geographic distribution of RSV in New South Wales.** Number of sequences per postcode  
 194 in NSW (left) and greater Westmead area (right). The location for Westmead Hospital is indicated.  
 195  
 196 **Table 1.** Demographic of the patient data used in this study. Ratios for gender and age categories are  
 197 shown for RSVA and RSVB. Total numbers are shown in brackets.

	RSVA (n = 64)		RSVB (n = 80)	
	Male	Female	Male	Female
Overall	0.453 (29)	0.547 (37)	0.550 (44)	0.438 (35)
<i>By Age groups</i>				
6 months or younger	0.094 (6)	0.078 (5)	0.163 (13)	0.075 (6)
7 months to 1 year	0.078 (5)	0.125 (8)	0.063 (5)	0.038 (3)
1 - 2 years	0.031 (2)	0.047 (3)	0.025 (2)	0.063 (5)
2 - 5 years	0.016 (1)	0.031 (2)	0.025 (2)	0.038 (3)
6 - 15 years	0.016 (1)	0.016 (1)	0.000 (0)	0.000 (0)
16 - 25 years	0.016 (1)	0.016 (1)	0.025 (2)	0.013 (1)
26 - 49 years	0.047 (3)	0.031 (2)	0.063 (5)	0.063 (5)
50 - 65 years	0.016 (1)	0.078 (5)	0.088 (7)	0.050 (4)
66 years or older	0.141 (9)	0.125 (8)	0.100 (8)	0.100 (8)

198  
 199 *3.2. Evolutionary history of RSV and spread within NSW*  
 200 To place our Australian RSV strains in the context of global RSV diversity, we performed an  
 201 evolutionary analysis using our genome sequences with global reference genomes sourced from  
 202 GenBank (Table S1). These sequences were sampled from 21 different countries across multiple  
 203 continents and spanned a time-span of 40 years ranging from 1977 to 2017. The final combined data  
 204 set consisted of 849 and 500 RSVA and RSVB genomes, respectively. While 21 countries were  
 205 represented in the data, there was a clear over-representation (n = 628) of viral genomes from the  
 206 USA, which comprised 46% of the data in this study. Other relatively well represented countries were  
 207 Peru (n = 122), the Netherlands (n = 61), Kenya (n = 61), Jordan (n = 85), Viet Nam (n = 53), New


208 Zealand ( $n = 92$ ), and the sequences sampled here in NSW ( $n = 144$ ). The extensive sampling biases  
 209 precluded detailed phylogeographic analyses. To simplify the geographic distribution analysis,  
 210 sequences were grouped according to their continent of sampling (Figures 3 and 4).  
 211



212

213 **Figure 3. Global phylogeny of RSVA and local clustering within NSW.** The maximum likelihood  
 214 tree shown was estimated using complete RSV genome sequences. Known genotypes and the  
 215 sequence time range is indicated. The tree is rooted using an RSVB outgroup (not shown),  
 216 respectively. Tree tips are colored according to the geographic region and sequences from this study  
 217 are shown in white. Local clusters comprising NSW sequences are marked within the global tree, and  
 218 the four clusters with potential multi-season transmission events are colored grey and enlarged on  
 219 the right side. Node supports are indicated, and branch lengths are scale according to the number of  
 220 substitutions per site.

221



222

223 **Figure 4. Global phylogeny of RSVB and local clustering within NSW.** The maximum likelihood  
 224 tree shown was estimated using complete RSV genome sequences. The tree is rooted using RSVA as  
 225 an outgroup and the BA and BA10 genotypes are marked. Tips colors represent sampling location  
 226 and sequences from this study are shown in white. Local clusters comprising NSW sequences are  
 227 marked within the global tree, and the three clusters with potential multi-season transmission events  
 228 are colored grey and enlarged on the right side. Node supports are indicated, and branch lengths are  
 229 scale according to the number of substitutions per site.

230

231 In both the RSVA and RSVB phylogenies, the earliest described RSV genomes were derived  
 232 solely from North America, and it is difficult to comment on the global distribution, diversity and  
 233 genetic sources until the early-mid 2000s when sampling became more evenly distributed. Since this  
 234 time, the global RSVA phylogeny has been dominated by viruses of the GA2 lineage, and more  
 235 recently, the ON1 sub-lineage (Figure 3), which is defined by a 72-nt duplication in the G gene [21].  
 236 In the global RSVB phylogeny, three sub-lineages of BA viruses have co-circulated, with the exception  
 237 of the most recent samples in which BA10 viruses appear to be dominant, although this could again  
 238 reflect sampling biases (Figure 4). In both phylogenies, distinct geographical clusters are clearly  
 239 visible. These sequences, sampled often from the same country and within a short time frame, are  
 240 seemingly indicative of local outbreaks following the importation of a globally predominant variant.  
 241 For example, there is a distinct cluster (Figure 3, yellow) of sequences from Kenya collected during

242 2010-2012, and a large cluster (Figure 4, light blue) of sequences sampled in Tennessee (USA) in 2013-  
243 2014.

244 The sequences from this study fell across the global RSVA and RSVB phylogenies, indicative of  
245 multiple entries of virus into NSW, both within and between individual RSV seasons (Figures 3 and  
246 4). We defined NSW-specific sequence clusters, as nodes with a majority of NSW sequences  
247 compared to the background of global sequences. Accordingly, we identified six and seven such  
248 clusters for RSVA and RSVB, respectively. For RSVA, all six NSW clusters were from the ON1  
249 genotype, five of which harbored sequences from 2016 (Figures 3). Due to the bias toward 2016 it was  
250 difficult to determine the extent of off-season RSV transmission (i.e. 'over-summering'). However,  
251 some evidence for the persistence of virus within Australia between RSV seasons was observed in  
252 2015 and 2016 (Figure 3, clusters I and II), and perhaps over multiple seasons (Figure 3, clusters II,  
253 III, and IV). However, the genetic distances between the sequences are large and node support is low,  
254 so that the clustering of sequences from different years is perhaps more likely to be due to limited  
255 sampling rather than actual virus persistence.

256 In the case of RSVB, six sequence pairs in individual clusters and the large BA10 genotype cluster  
257 were identified (Figure 4). Potential multiple entries might have occurred in 2012 and 2016 for the BA  
258 genotype, excluding the BA10 cluster, although this inference is again based on only a small number  
259 of sequences. Interestingly, there is some evidence for multi-season persistence from 2011 to 2012 and  
260 2015 to 2016, although this will clearly need to be confirmed with larger data sets (Figure 4, clusters  
261 I and II). Similarly, within the BA10 genotype there is some evidence of multi-year persistence from  
262 2015 to 2016 (Figure 4, cluster III, WM2082A). The BA10 genotype contains Australian sequences  
263 sampled between 2013 and 2016 sequences from USA, China, New Zealand, England, and Japan,  
264 with the latter the most recent sequence sampled in 2017, and thus, the BA10 genotype likely  
265 represents the most recent global circulating RSVB variant.

266

### 267 3.3. Geographic and age structure of RSV infections in NSW


268 For the most comprehensive sampled year, 2016, we assessed the extent to which the  
269 phylogenetic structure in the data reflected patient age or geographic structure. Accordingly, the  
270 facility (hospital or clinic) where the patient first presented, patient electorate, and patient age were  
271 mapped across the tree (Table S2). Thirteen different facilities were associated with RSVA, although  
272 six facilities were associated with one sequence only. Similarly, RSVB was represented by 18 facilities,  
273 nine of which were represented by one sequence only. Nevertheless, one facility, Young Hospital  
274 (located in rural NSW) contained four RSVA sequences and exhibited significant clustering with a *p*-  
275 value of 0.001 (Table S2, RSVA). These sequences were sampled in August and September and most  
276 likely represent a distinct local outbreak as genetic diversity was low (Figure 3, cluster II, WM1339A,  
277 WM2841A, WM2209A & WM4313A). All four sequences were sampled from patients residing in the  
278 Cootamundra electorate, which is also the electorate with the lowest *p*-value (0.002). The significant  
279 clustering for facility and electorate is also supported by the low parsimony score (PS) and association  
280 index (AI) values, i.e. 0.00 and 0.006 for facility and electorate, respectively. Surprisingly, no  
281 significant clustering was observed in the case of RSVB despite different geographic locations and  
282 age categories being well represented in the data (Table S2). Notably, however, both the AI and PS  
283 statistics are highly conservative [46], as the null model assumes complete panmixis, and thus weak  
284 significance may in fact indicate relatively frequent virus movement. This is supported by the

285 observation that the best sampled localities often exhibited the least geographic clustering, arguing  
 286 against *in situ* transmission. For example, Mount Druitt Hospital and Westmead Hospital were the  
 287 best sampled facilities (13 and 11 sequences for RSVA and RSVB, respectively) but exhibited non-  
 288 significant geographic clustering ( $p = 0.730$ , and 1.00, respectively). Finally, we also investigated the  
 289 extent of phylogenetic clustering by patient age group, particularly as RSV mainly infects infants.  
 290 Notably, none of the age groups showed significant clustering in RSVA or RSVB (Table S2). Hence,  
 291 these data indicate that the same virus lineages were able to infect and circulate within multiple age  
 292 groups.

293

294 *3.3. Evolutionary dynamics of RSV*

295 Previous studies have reported a difference in evolutionary rates between the two subtypes,  
 296 particularly that the G gene had significantly higher rates in RSVB than RSVA [20, 47]. As the global  
 297 RSV data is highly biased in time and space, we examined evolutionary dynamics at both the global  
 298 scale and within the NSW sequences alone. To assess the extent of clock-like structure in the data, we  
 299 first performed a simple regression of genome-scale root-to-tip genetic distances against year of  
 300 sampling with TempEst v.1.5 [36] using the RSVA and RSVB ML trees. This provided evidence for a  
 301 very strong molecular clock signal, with  $R^2$  values of 0.951 and 0.927 for RSVA and RSVB,  
 302 respectively, for the NSW sequences, and 0.978 and 0.990 for the global sequences (Figure 5A&B).  
 303 Under this regression method, the mean rates of nucleotide substitution were also very similar at 7.97  
 304 and  $7.62 \times 10^{-4}$  substitutions per site per year (subs/site/year) for global RSVA and RSVB, respectively,  
 305 and 7.29 and  $7.56 \times 10^{-4}$  subs/site/year for RSVA and RSVB sampled in NSW in this study, respectively  
 306 (Figure 5A).  
 307



308 **Figure 5. Evolutionary rates in RSV.** (A) Linear regressions of root-to-tip genetic distances against  
 309 sampling date based on maximum likelihood trees. The  $R^2$  value for each regression is indicated and  
 310 corresponding  $p$  values  $< 0.001$  are indicated with asterisk. Sequences from NSW in this study are  
 311 shown on the left and global sequences on the right. (B) Estimates of nucleotide substitution rate per  
 312 site, per year are shown for sequences from NSW (BEAST and LSD estimates) and globally (LSD  
 313 estimates). Rates are shown as mean values (circles) and the 95% HPD (error bar). (RSVA: blue; RSVB:  
 314 red).

316

317 Given this strong clock-like structure, we investigated evolutionary rates more carefully using  
 318 the Bayesian Markov chain Monte Carlo (MCMC) method implemented in BEAST for the NSW data  
 319 set, and the least square dating (LSD) method for the global data set. In the case of the NSW data, the  
 320 mean evolutionary rates were  $6.48 \times 10^{-4}$  (confidence interval HPD  $5.15 - 7.81 \times 10^{-4}$ ) and  $7.06 \times 10^{-4}$   
 321 (confidence interval  $6.07 - 8.07 \times 10^{-4}$ ) subs/site/year for RSVA and RSVB, respectively, using LSD,

322 and  $7.48 \times 10^{-4}$  (95% HPD  $6.67 - 8.34 \times 10^{-4}$ ) and  $7.39 \times 10^{-4}$  (95% HPD  $6.34 - 8.45 \times 10^{-4}$ ) subs/site/year  
323 for RSVA and RSVB, respectively, using BEAST (Figure 5B). Hence, there was no significant  
324 difference in rate between RSVA and RSVB. For the global data set LSD rate estimates were  $5.72 \times 10^{-4}$   
325 (confidence interval  $5.43 - 5.95 \times 10^{-4}$ ) and  $6.41 \times 10^{-4}$  (confidence interval  $6.02 - 6.78 \times 10^{-4}$ )  
326 subs/site/year for RSVA and RSVB, respectively. These rates are within the range reported previously  
327 for paramyxoviruses [48] and other single-stranded RNA viruses [49]. Notably, the substitution rates  
328 for the global data set were significantly different between RSVA and RSVB, and RSVB exhibited a  
329 higher rate, as previously described [20]. These global rates were also consistently lower than those  
330 observed within NSW (for both BEAST and LSD), and there was no difference between RSVA and  
331 RSVB in the NSW data set. This difference between the local (NSW) and global rates may reflect the  
332 fact that the NSW data were sampled more recently sample, and that rates are elevated towards the  
333 present because of time-dependent evolution, itself reflecting incomplete purifying selection, that is  
334 commonly observed in RNA viruses [50, 51].

### 335 5. Conclusions

336 We report a wide diversity of RSV lineages co-circulating in a small geographic region, reflecting  
337 a combination of continual virus entry and some sustained *in situ* transmission within NSW. Despite  
338 these fine-scale epidemiological insights, this study also highlighted the highly biased global  
339 sampling of RSV that hinders extensive analysis on the global distribution and transmission  
340 dynamics of RSV. We stress that increased targeted surveillance with more extensive virus sampling,  
341 particularly during suspected outbreaks, is essential to improve both our understanding of RSV  
342 ecology and evolution, and assist with vaccine design.

343 **Supplementary Materials:** The following are available online at [www.mdpi.com/xxx/s1](http://www.mdpi.com/xxx/s1), Table S1: Accession  
344 numbers; Table S2: Phylogeny-trait association test for RSV in Australia.

345 **Author Contributions:** Conceptualization, J.-S.E., J.K., and E.C.H.; Methodology, J.-S.E., M.F., and F.D.G.;  
346 Resources, J.K., I.C., and D.E.D.; Data Curation, J.-S.E.; Formal analysis; F.D.G., J.G., and J.-S.E.; Visualization,  
347 F.D.G., and J.-S.E.; Writing-Original Draft Preparation, F.D.G., J.-S.E., and E.C.H.; Supervision, J.-S.E., J.K., D.E.D.,  
348 and E.C.H.; Project Administration, J.K., and E.C.H.; Funding Acquisition, E.C.H.

349 **Funding:** This research was funded by the Australian Research Council grant number FL170100022 to E.C.H.,  
350 and support through the Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney.

351 **Acknowledgments:** The authors acknowledge the Sydney Informatics Hub and the University of Sydney's high-  
352 performance computing cluster Artemis for providing the high-performance computing resources that have  
353 contributed to the research results reported within this paper.

354 **Conflicts of Interest:** The authors declare no conflict of interest.

### 355 References

- 356 1. Nair, H.; Nokes, D. J.; Gessner, B. D.; Dherani, M.; Madhi, S. A.; Singleton, R. J.; O'Brien, K. L.; Roca, A.;  
357 Wright, P. F.; Bruce, N.; *et al.* Global burden of acute lower respiratory infections due to respiratory  
358 syncytial virus in young children: a systematic review and meta-analysis. *Lancet* **2010**, *375*, 1545–1555  
359 10.1016/S0140-6736(10)60206-1
- 360 2. Caram, L. B.; Chen, J.; Taggart, E. W.; Hillyard, D. R.; She, R.; Polage, C. R.; Twersky, J.; Schmader, K.;  
361 Petti, C. A.; Woods, C. W. Respiratory syncytial virus outbreak in a long-term care facility detected  
362 using reverse transcriptase polymerase chain reaction: an argument for real-time detection methods. *J. Am. Geriatr. Soc.* **2009**, *57*, 482–485 10.1111/j.1532-5415.2008.02153.x

364 3. Shi, T.; McAllister, D. A.; O'Brien, K. L.; Simoes, E. A. F.; Madhi, S. A.; Gessner, B. D.; Polack, F. P.;  
365 Balsells, E.; Acacio, S.; Aguayo, C.; *et al.* Global, regional, and national disease burden estimates of acute  
366 lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic  
367 review and modelling study. *Lancet* **2017**, *390*, 946-958 10.1016/S0140-6736(17)30938-8

368 4. Nolan, T.; Borja-Tabora, C.; Lopez, P.; Weckx, L.; Ulloa-Gutierrez, R.; Lazcano-Ponce, E.; Kerdpanich,  
369 A.; Weber, M. A. R.; de Los Santos, A. M.; Tinoco, J. C.; *et al.* Prevalence and incidence of respiratory  
370 syncytial virus and other respiratory viral infections in children aged 6 months to 10 years with  
371 influenza-like illness enrolled in a randomized trial. *Clin. Infect. Dis.* **2015**, *60*, E80-E89  
372 10.1093/cid/civ065

373 5. Ranmuthugala, G.; Brown, L.; Lidbury, B. A. Respiratory syncytial virus - the unrecognised cause of  
374 health and economic burden among young children in Australia. *Commun. Dis. Intell.* **2011**, *35*, 177-184

375 6. Fagan, P.; McLeod, C.; Baird, R. W. Seasonal variability of respiratory syncytial virus infection in the  
376 Top End of the Northern Territory (2012-2014). *J. Paediatr. Child Health* **2017**, *53*, 43-46 10.1111/jpc.13303

377 7. Whitehall, J. S.; Bolisetty, S.; Whitehall, J. P.; Francis, F.; Norton, R.; Patole, S. K. High rate of indigenous  
378 bronchiolitis and palivuzumab. *J. Paediatr. Child Health* **2001**, *37*, 416-417

379 8. CDC Respiratory syncytial virus infection (RSV). <https://www.cdc.gov/rsv/index.html> (accessed on 05  
380 April 2018),

381 9. Collins, P. L.; Dickens, L. E.; Buckler-White, A.; Olmsted, R. A.; Spriggs, M. K.; Camargo, E.; Coelingh,  
382 K. V. Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal  
383 distinctive features of intergenic structure and gene order. *Proc. Natl. Acad. Sci. U. S. A.* **1986**, *83*, 4594-  
384 4598

385 10. Anderson, L. J.; Hierholzer, J. C.; Tsou, C.; Hendry, R. M.; Fernie, B. F.; Stone, Y.; McIntosh, K. Antigenic  
386 characterization of respiratory syncytial virus strains with monoclonal antibodies. *J. Infect. Dis.* **1985**,  
387 *151*, 626-633

388 11. Johnson, P. R.; Spriggs, M. K.; Olmsted, R. A.; Collins, P. L. The G glycoprotein of human respiratory  
389 syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related  
390 proteins. *Proc. Natl. Acad. Sci. U. S. A.* **1987**, *84*, 5625-5629

391 12. Bouvier, N. M.; Palese, P. The biology of influenza viruses. *Vaccine* **2008**, *26*, D49-53

392 13. Cane, P. A.; Pringle, C. R. Evolution of subgroup A respiratory syncytial virus: evidence for progressive  
393 accumulation of amino acid changes in the attachment protein. *J. Virol.* **1995**, *69*, 2918-2925

394 14. Bont, L.; Versteegh, J.; Swelsen, W. T.; Heijnen, C. J.; Kavelaars, A.; Brus, F.; Draisma, J. M.;  
395 Pekelharing-Berghuis, M.; van Diemen-Stenvoorde, R. A.; Kippen, J. L. Natural reinfection with  
396 respiratory syncytial virus does not boost virus-specific T-cell immunity. *Pediatr. Res.* **2002**, *52*, 363-367  
397 10.1203/00006450-200209000-00009

398 15. Henderson, F. W.; Collier, A. M.; Clyde, W. A., Jr.; Denny, F. W. Respiratory-syncytial-virus infections,  
399 reinfections and immunity. A prospective, longitudinal study in young children. *N. Engl. J. Med.* **1979**,  
400 *300*, 530-534 10.1056/NEJM197903083001004

401 16. Graham, B. S. Vaccine development for respiratory syncytial virus. *Curr. Opin. Virol.* **2017**, *23*, 107-112  
402 10.1016/j.coviro.2017.03.012

403 17. Shook, B. C.; Lin, K. Recent advances in developing antiviral therapies for respiratory syncytial virus.  
404 *Top. Curr. Chem.* **2017**, *375*, 10.1007/s41061-017-0129-4

405 18. Martinez, I.; Valdes, O.; Delfraro, A.; Arbiza, J.; Russi, J.; Melero, J. A. Evolutionary pattern of the G  
406 glycoprotein of human respiratory syncytial viruses from antigenic group B: the use of alternative

407 termination codons and lineage diversification. *J. Gen. Virol.* **1999**, *80*, 125–130 10.1099/0022-1317-80-1-  
408 125

409 19. Sullender, W. M.; Mufson, M. A.; Anderson, L. J.; Wertz, G. W. Genetic diversity of the attachment  
410 protein of subgroup B respiratory syncytial viruses. *J. Virol.* **1991**, *65*, 5425–5434

411 20. Schobel, S. A.; Stucker, K. M.; Moore, M. L.; Anderson, L. J.; Larkin, E. K.; Shankar, J.; Bera, J.; Puri, V.;  
412 Shilts, M. H.; Rosas-Salazar, C.; *et al.* Respiratory syncytial virus whole-genome sequencing identifies  
413 convergent evolution of sequence duplication in the C-terminus of the G gene. *Sci. Rep.* **2016**, *6*, 26311  
414 10.1038/srep26311

415 21. Trento, A.; Casas, I.; Calderon, A.; Garcia-Garcia, M. L.; Calvo, C.; Perez-Brena, P.; Melero, J. A. Ten  
416 years of global evolution of the human respiratory syncytial virus BA genotype with a 60-nucleotide  
417 duplication in the G protein gene. *J. Virol.* **2010**, *84*, 7500–7512 10.1128/JVI.00345-10

418 22. Agoti, C. N.; Otieno, J. R.; Munywoki, P. K.; Mwihuri, A. G.; Cane, P. A.; Nokes, D. J.; Kellam, P.; Cotten,  
419 M. Local evolutionary patterns of human respiratory syncytial virus derived from whole-genome  
420 sequencing. *J. Virol.* **2015**, *89*, 3444–3454 10.1128/JVI.03391-14

421 23. Brandenburg, A. H.; van Beek, R.; Moll, H. A.; Osterhaus, A. D.; Claas, E. C. G protein variation in  
422 respiratory syncytial virus group A does not correlate with clinical severity. *J. Clin. Microbiol.* **2000**, *38*,  
423 3849–3852

424 24. Martinelli, M.; Frati, E. R.; Zappa, A.; Ebranati, E.; Bianchi, S.; Pariani, E.; Amendola, A.; Zehender, G.;  
425 Tanzi, E. Phylogeny and population dynamics of respiratory syncytial virus (Rsv) A and B. *Virus Res.*  
426 **2014**, *189*, 293–302 10.1016/j.virusres.2014.06.006

427 25. Pretorius, M. A.; van Niekerk, S.; Tempia, S.; Moyes, J.; Cohen, C.; Madhi, S. A.; Venter, M.; Group, S.  
428 S. Replacement and positive evolution of subtype A and B respiratory syncytial virus G-protein  
429 genotypes from 1997–2012 in South Africa. *J. Infect. Dis.* **2013**, *208*, S227–237 10.1093/infdis/jit477

430 26. Tan, L.; Lemey, P.; Houspie, L.; Viveen, M. C.; Jansen, N. J.; van Loon, A. M.; Wiertz, E.; van Bleek, G.  
431 M.; Martin, D. P.; Coenjaerts, F. E. Genetic variability among complete human respiratory syncytial  
432 virus subgroup A genomes: bridging molecular evolutionary dynamics and epidemiology. *PLoS One*  
433 **2012**, *7*, e51439 10.1371/journal.pone.0051439

434 27. Bose, M. E.; He, J.; Shrivastava, S.; Nelson, M. I.; Bera, J.; Halpin, R. A.; Town, C. D.; Lorenzi, H. A.;  
435 Noyola, D. E.; Falcone, V.; *et al.* Sequencing and analysis of globally obtained human respiratory  
436 syncytial virus A and B genomes. *PLoS One* **2015**, *10*, e0120098 10.1371/journal.pone.0120098

437 28. Bolger, A. M.; Lohse, M.; Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data.  
438 *Bioinformatics* **2014**, *30*, 2114–2120 10.1093/bioinformatics/btu170

439 29. Grabherr, M. G.; Haas, B. J.; Yassour, M.; Levin, J. Z.; Thompson, D. A.; Amit, I.; Adiconis, X.; Fan, L.;  
440 Raychowdhury, R.; Zeng, Q.; *et al.* Full-length transcriptome assembly from RNA-Seq data without a  
441 reference genome. *Nat. Biotechnol.* **2011**, *29*, 644–652 10.1038/nbt.1883

442 30. Bankevich, A.; Nurk, S.; Antipov, D.; Gurevich, A. A.; Dvorkin, M.; Kulikov, A. S.; Lesin, V. M.;  
443 Nikolenko, S. I.; Pham, S.; Prjibelski, A. D.; *et al.* SPAdes: a new genome assembly algorithm and its  
444 applications to single-cell sequencing. *J. Comput. Biol.* **2012**, *19*, 455–477 10.1089/cmb.2012.0021

445 31. Langmead, B.; Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat. Methods* **2012**, *9*, 357–359  
446 10.1038/nmeth.1923

447 32. Kuraku, S.; Zmasek, C. M.; Nishimura, O.; Katoh, K. aLeaves facilitates on-demand exploration of  
448 metazoan gene family trees on MAFFT sequence alignment server with enhanced interactivity. *Nucleic  
449 Acids Res.* **2013**, *41*, W22–W28 10.1093/nar/gkt389

450 33. Martin, D. P.; Murrell, B.; Golden, M.; Khoosal, A.; Muhire, B. RDP4: Detection and analysis of  
451 recombination patterns in virus genomes. *Virus Evol.* **2015**, *1*, 10.1093/ve/vev003

452 34. Stamatakis, A. RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of  
453 taxa and mixed models. *Bioinformatics* **2006**, *22*, 2688-2690 10.1093/bioinformatics/btl446

454 35. Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large  
455 phylogenies. *Bioinformatics* **2014**, *30*, 1312-1313 10.1093/bioinformatics/btu033

456 36. Rambaut, A.; Lam, T. T.; Carvalho, L. M.; Pybus, O. G. Exploring the temporal structure of  
457 heterochronous sequences using TempEst (formerly Path-O-Gen). *Virus Evol.* **2016**, *2*,  
458 10.1093/ve/vew007

459 37. Drummond, A. J.; Suchard, M. A.; Xie, D.; Rambaut, A. Bayesian phylogenetics with BEAUti and the  
460 BEAST 1.7. *Mol. Biol. Evol.* **2012**, *29*, 1969-1973 10.1093/molbev/mss075

461 38. To, T. H.; Jung, M.; Lycett, S.; Gascuel, O. Fast dating using least-squares criteria and algorithms. *Syst.*  
462 *Biol.* **2016**, *65*, 82-97 10.1093/sysbio/syv068

463 39. Duchene, S.; Duchene, D. A.; Geoghegan, J. L.; Dyson, Z. A.; Hawkey, J.; Holt, K. E. Inferring  
464 demographic parameters in bacterial genomic data using Bayesian and hybrid phylogenetic methods.  
465 *BMC Evol. Biol.* **2018**, *18*, 10.1186/s12862-018-1210-5

466 40. Parker, J.; Rambaut, A.; Pybus, O. G. Correlating viral phenotypes with phylogeny: accounting for  
467 phylogenetic uncertainty. *Infect. Genet. Evol.* **2008**, *8*, 239-246 10.1016/j.meegid.2007.08.001

468 41. Fall, A.; Dia, N.; Cisse el, H. A.; Kiori, D. E.; Sarr, F. D.; Sy, S.; Goudiaby, D.; Richard, V.; Niang, M. N.  
469 Epidemiology and molecular characterization of human respiratory syncytial virus in senegal after four  
470 consecutive years of surveillance, 2012-2015. *PLoS One* **2016**, *11*, e0157163 10.1371/journal.pone.0157163

471 42. Rodriguez-Fernandez, R.; Tapia, L. I.; Yang, C. F.; Torres, J. P.; Chavez-Bueno, S.; Garcia, C.; Jaramillo,  
472 L. M.; Moore-Clingenpeel, M.; Jafri, H. S.; Peebles, M. E.; *et al.* Respiratory syncytial virus genotypes,  
473 host immune profiles, and disease severity in young children hospitalized with bronchiolitis. *J. Infect.*  
474 *Dis.* **2018**, *217*, 24-34 10.1093/infdis/jix543

475 43. Tabatabai, J.; Prifert, C.; Pfeil, J.; Grulich-Henn, J.; Schnitzler, P. Novel respiratory syncytial virus (RSV)  
476 genotype ON1 predominates in Germany during winter season 2012-13. *PLoS One* **2014**, *9*, e109191  
477 10.1371/journal.pone.0109191

478 44. Thongpan, I.; Mauleekoonphairoj, J.; Vichiwattana, P.; Korkong, S.; Wasitthankasem, R.;  
479 Vongpunsawad, S.; Poovorawan, Y. Respiratory syncytial virus genotypes NA1, ON1, and BA9 are  
480 prevalent in Thailand, 2012-2015. *PeerJ* **2017**, *5*, e3970 10.7717/peerj.3970

481 45. Geoghegan, J. L.; Saavedra, A. F.; Duchene, S.; Sullivan, S.; Barr, I.; Holmes, E. C. Continental  
482 synchronicity of human influenza virus epidemics despite climatic variation. *PLoS Pathog.* **2018**, *14*,  
483 e1006780 10.1371/journal.ppat.1006780

484 46. Slatkin, M.; Maddison, W. P. A cladistic measure of gene flow inferred from the phylogenies of alleles.  
485 *Genetics* **1989**, *123*, 603-613

486 47. Tan, L.; Coenjaerts, F. E.; Houspie, L.; Viveen, M. C.; van Bleek, G. M.; Wiertz, E. J.; Martin, D. P.; Lemey,  
487 P. The comparative genomics of human respiratory syncytial virus subgroups A and B: genetic  
488 variability and molecular evolutionary dynamics. *J. Virol.* **2013**, *87*, 8213-8226 10.1128/JVI.03278-12

489 48. Pomeroy, L. W.; Bjornstad, O. N.; Holmes, E. C. The evolutionary and epidemiological dynamics of the  
490 paramyxoviridae. *J. Mol. Evol.* **2008**, *66*, 98-106 10.1007/s00239-007-9040-x

491 49. Duffy, S.; Shackelton, L. A.; Holmes, E. C. Rates of evolutionary change in viruses: patterns and  
492 determinants. *Nat. Rev. Genet.* **2008**, *9*, 267-276 10.1038/nrg2323

493 50. Duchene, S.; Ho, S. Y. W.; Holmes, E. C. Declining transition/transversion ratios through time reveal  
494 limitations to the accuracy of nucleotide substitution models. *BMC Evol. Biol.* **2015**, *15*, 10.1186/s12862-  
495 015-0312-6

496 51. Duchene, S.; Holmes, E. C.; Ho, S. Y. Analyses of evolutionary dynamics in viruses are hindered by a  
497 time-dependent bias in rate estimates. *Proc. Biol. Sci.* **2014**, *281*, 10.1098/rspb.2014.0732

498